This study highlights the potential use of FXR and PPARγ agonists as well as of the therapeutic p17 vaccine or small molecule inhibitors as potential agents for the treatment of immune and metabolic dysfunction in HIV infection. The gene discussed is NR1H4; the disease is HIV infectious disease.